FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2026/04/107563 [Registered on: 06/04/2026] Trial Registered Prospectively
Last Modified On: 23/03/2026
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Surgical/Anesthesia 
Study Design  Randomized, Parallel Group Trial 
Public Title of Study   ICG Fluorescence-Guided vs Conventional approach on surgical outcomes in Pancreatic Head Resection for Chronic Pancreatitis  
Scientific Title of Study   Effect Of Indocyanine Green Fluorescence Guided Real Time Surgery Vs Conventional Approach on Surgical Outcomes in Patients Undergoing Bile Duct and Duodenum Preserving Pancreatic Head Resection Surgery for Chronic Pancreatitis- A Randomized Controlled Trial 
Trial Acronym  nil 
Secondary IDs if Any  
Secondary ID  Identifier 
nil  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Greeshma Unnikrishnan 
Designation  Junior Resident 
Affiliation  Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry 
Address  Junior Resident Department of Surgery Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry JIPMER Campus Rd, Gorimedu Dhanvantari Nagar Puducherry

Pondicherry
PONDICHERRY
605006
India 
Phone  8296658292  
Fax    
Email  greeshma.ushus@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Shanmugam D 
Designation  Professor 
Affiliation  Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry 
Address  Professor Department of Surgery Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry JIPMER Campus Rd, Gorimedu Dhanvantari Nagar Puducherry

Pondicherry
PONDICHERRY
605006
India 
Phone  9787273017  
Fax    
Email  shandsge@gmail.com   
 
Details of Contact Person
Public Query
 
Name  Dr Shanmugam D 
Designation  Professor 
Affiliation  Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry 
Address  Professor Department of Surgery Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry JIPMER Campus Rd, Gorimedu Dhanvantari Nagar Puducherry

Pondicherry
PONDICHERRY
605006
India 
Phone  9787273017  
Fax    
Email  shandsge@gmail.com   
 
Source of Monetary or Material Support  
Jawaharlal Institute of Postgraduate Medical Education and Research, JIPMER Campus Rd, Gorimedu, Dhanvantari Nagar, Puducherry - 605006, India 04132296562 
 
Primary Sponsor  
Name  Dr. Greeshma Unnikrishnan 
Address  Junior Resident Department of Surgery Jawaharlal Institute of Postgraduate Medical Education and Research JIPMER Campus Rd Gorimedu Dhanvantari Nagar Puducherry 605006 
Type of Sponsor  Other [Self] 
 
Details of Secondary Sponsor  
Name  Address 
nil  nil 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Greeshma Unnikrishnan  Jawaharlal Institute of Postgraduate Medical Education and Research  Department of Surgery and Surgical Gastroenterology
Pondicherry
PONDICHERRY 
8296658292

greeshma.ushus@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
INSTITUTIONAL ETHICS COMMITTEE-INTERVENTIONAL STUDIES JIPMER, PUDUCHERRY  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: K861||Other chronic pancreatitis,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Patients undergo Bile duct and Duodenum preserving pancreatic head resection with intraoperative indocyanine green (ICG) fluorescence for real-time cholangiography to identify the bile duct and intravenous angiography to visualize vascular arcades and to assess duodenal perfusion.   Under strict aseptic precautions, one vial of indocyanine green (ICG) containing 25 mg of lyophilized dye will be reconstituted with 10 mL of sterile water for injection, thereby yielding a concentration of 2.5 mg/mL. The reconstituted vial will be used within six hours to maintain stability of the dye. A test dose of 0.1 mL will be administered intravenously under anaesthetic monitoring to detect any allergic or adverse reaction. For biliary mapping, single dose administration of ICG will be done intravenously at a dose of 2.5 mg approximately 60 minutes before skin incision.The surgical technique of DPPHR will be performed according to standard steps: Kocherization of the duodenum, exposure of the pancreatic head, coring of inflammatory pancreatic tissue, careful preservation of the bile duct, hemostasis, and reconstruction of the pancreatic remnant. For arterial and duodenal arcade perfusion assessment, 5 mg IV will be injected during mobilization or after pancreatic head coring, followed by a 10 mL saline flush. Near-infrared (NIR) light will be used to record perfusion parameters. Fluorescence will be visualized with an open-surgery compatible near-infrared (NIR) system. The duration of the intervention would be approximately 15 minutes for the injection of the dye, and observation of bile duct and vascular arcades.  
Comparator Agent  Patients undergo standard DPPHR without ICG; bile duct and perfusion are assessed by conventional anatomical dissection and visual cues alone.   The surgical technique of DPPHR will be performed according to standard steps: Kocherization of the duodenum, exposure of the pancreatic head, coring of inflammatory pancreatic tissue, careful preservation of the bile duct, hemostasis, and reconstruction of the pancreatic remnant. Bile duct and perfusion are assessed by conventional anatomical dissection and visual cues alone.  
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  90.00 Year(s)
Gender  Both 
Details  Adult patients with chronic pancreatiitis requiring surgical management 
 
ExclusionCriteria 
Details  1. Patients with Chronic Pancreatitis with suspicion of malignancy

2. Previous pancreatic surgeries

3. Portal hypertension with varices or major vascular thrombosis.

4. Severe hepatic or renal impairment eGFR less than 30 mL/min/1.73m²).

5. Patients with Chronic Pancreatitis with distal biliary stricture

6. Patients with Chronic Pancreatitis who many require additional surgical procedures (Cystojejunostomy, Distal pancreatectomy, Splenectomy)

7. Known allergy to ICG or iodides.
8. Pregnancy or lactation.
 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Sequentially numbered, sealed, opaque envelopes 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
To determine whether using indocyanine green (ICG) fluorescence during surgery lowers the risk of bile duct-related complications in patients undergoing bile duct and duodenum-preserving pancreatic head resection (DPPHR), such as intraoperative injury, postoperative bile leak, or stricture within 90 days  To determine whether using indocyanine green (ICG) fluorescence during surgery lowers the risk of bile duct-related complications in patients undergoing bile duct and duodenum-preserving pancreatic head resection (DPPHR), such as intraoperative injury, postoperative bile leak, or stricture within 90 days 
 
Secondary Outcome  
Outcome  TimePoints 
To compare overall morbidity within 30 days classified by Clavien–Dindo grade, length of hospital stay (days) & readmission within 30 days between the ICG & non ICG groups.

To compare functional endocrine & exocrine outcomes at 90 days between the ICG & non ICG groups.

To compare the adequacy of head coring at 3 months (defined as absence of more than 5 mm residual pancreatic head tissue) radiologically using CT, postoperative pain reduction using COMPAT-SF score, & quality of life using EORTC C30 global health score between the ICG & non ICG groups.

To assess the proportion of patients with preserved duodenal perfusion confirmed by ICG angiography (uniform fluorescence of duodenum within 60 seconds of injection).

To assess ICG-related adverse events (anaphylaxis, urticaria, hypotension, or injection-site reactions) documented perioperatively.
 
Overall morbidity will be assessed within 30 days

Functional endocrine & exocrine outcomes will be assessed at 90 days.

Adequacy of head coring will be assessed at 90 days.

Post opertaive pain reduction & quality of life will be assessed ay 90 days.

Proportion of patients with preserved duodenal perfusion will be assessed as uniform fluorescence of duodenum within 60 seconds of injection

ICG related adverse events will be documented perioperatively

 
 
Target Sample Size   Total Sample Size="36"
Sample Size from India="36" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 3 
Date of First Enrollment (India)   06/04/2026 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="3"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Yet Recruiting 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Bile Duct and Duodenum-preserving pancreatic head resection (DPPHR) is a function-preserving surgical alternative to pancreatoduodenectomy for patients with chronic pancreatitis. By preserving the duodenum and distal bile duct, DPPHR provides effective long-term pain relief while maintaining pancreatic endocrine and exocrine function and improving nutritional outcomes. Several meta-analyses and long-term studies have demonstrated that DPPHR leads to superior functional outcomes compared to pancreatoduodenectomy, including lower rates of new-onset diabetes and exocrine insufficiency. However, achieving adequate pancreatic head coring is crucial for effective pain control, while excessive resection may compromise the common bile duct (CBD) or surrounding vascular structures. Protecting the CBD and maintaining duodenal vascularity remain significant intraoperative challenges, particularly in patients with distorted anatomy due to chronic inflammatory fibrosis. Conventional techniques depend largely on the surgeon’s experience and visual assessment, which may not consistently ensure ductal safety or adequate perfusion.

Indocyanine green (ICG) fluorescence imaging is a technique that enables real-time intraoperative cholangiography and perfusion assessment. Early studies suggest that ICG-guided DPPHR may improve visualization of the bile duct, confirm adequate duodenal vascularity, and help assess the completeness of pancreatic head resection. However, existing evidence is limited, as most studies are retrospective with small sample sizes and focus mainly on technical feasibility. There is a lack of randomized controlled trials (RCTs) evaluating the effectiveness of ICG guidance in DPPHR.

To address this gap, the present study is designed as a prospective RCT comparing DPPHR performed with ICG guidance to conventional DPPHR without fluorescence imaging. The study will be conducted in the Department of Surgery and Surgical Gastroenterology at JIPMER. Patients with chronic pancreatitis planned for open bile duct and duodenum-preserving pancreatic head resection will be screened for eligibility and enrolled after informed consent. Preoperative evaluation will include demographic details, clinical examination, laboratory investigations, and imaging to assess pancreatic, biliary, and vascular anatomy.

Participants will be divided into two groups. The intervention group will undergo ICG-guided DPPHR, where intraoperative fluorescence imaging will be used for real-time identification of the bile duct and evaluation of duodenal and arterial arcade perfusion. The control group will undergo conventional DPPHR based on standard anatomical dissection and visual assessment. ICG will be administered intravenously following standardized hepatopancreatobiliary surgery protocols. A dose of 2.5 mg will be given approximately 60 minutes before incision for biliary mapping, while an additional 5 mg will be administered intraoperatively to assess arterial and duodenal perfusion using near-infrared imaging. Perfusion parameters such as time to fluorescence (Tmax) and half-rise time (T½MAX) will be recorded to evaluate vascular adequacy.

Fluorescence imaging will be performed at three standardized intraoperative stages: before pancreatic head coring for biliary mapping, after coring to assess arterial arcade perfusion, and before closure to detect bile leaks or compromised vascularity. Intraoperative data collected will include operative time, blood loss, transfusion requirements, complications, and ICG dosing. Postoperative monitoring will follow enhanced recovery after surgery (ERAS) protocols, with assessment of complications such as cholangitis, obstructive jaundice, bile leak, bile duct stricture, pancreatic fistula, intra-abdominal collections, and delayed gastric emptying according to established international criteria.

The primary outcome of the study will be the incidence of bile duct injury or postoperative bile leak within 90 days. Secondary outcomes will include accuracy of biliary identification, adequacy of duodenal perfusion, operative parameters, postoperative morbidity, hospital stay, and reintervention rates. Fluorescence recordings will be independently evaluated by to assess signal strength, completeness, and homogeneity.

 
Close